Blood cancers lead in CAR-T therapy development: report | Healthcare Asia Magazine
Photo from Envato

Blood cancers lead in CAR-T therapy development: report

Currently, 13 CAR-T treatments have received regulatory approval.

Blood cancers have dominated the development pipeline of chimeric antigen receptor T-cell (CAR-T) therapeutics, according to GlobalData.

“Blood cancers account for over half of all CAR-Ts in the active pipeline and make up nine out of the top 10 CAR-T indications,” the report said.

CAR-T therapies are developed by engineering T-cells to express chimeric antigen receptors capable of identifying and destroying cancerous cells.

The therapy accounts for over half of oncology cell and gene therapy approvals, with 13 CAR-T treatments currently receiving regulatory approval.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!